To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.
March 20-22nd, 2017 | Barcelona, Spain | Bio Europe Spring
XenTech is pleased to attend to the 11th BIO Europe Spring event on March in Barcelona. It is the perfect occasion to meet you and talk about your projects in preclinical development of anti cancer drugs. More info about this partnering conference here. To set up a meeting with our dedicated team, send us a […]
Contract Research Organization
XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....